UC (urothelial)
Oncology · 2018–2023
3decisions
2medicines
3carried consumer input
10individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| nivolumab Adjuvant treatment of high-risk muscle invasive urothelial carcinoma (MIUC) after radical resection in patients who have received prior neoadjuvant… | Nov 2023 | Deferred | input received |
| nivolumab Adjuvant treatment of patients with muscle invasive urothelial carcinoma (MIUC) who have undergone radical resection and are at high risk of recurrence. | Jul 2022 | Not recommended | input received BEAT Bladder Cancer Australia · Medical Oncology Group · New York Heart Association |
| pembrolizumab Locally advanced or metastatic urothelial cancer after failure of platinum-based therapy. | Jul 2018 | Recommended with restriction | 10 individuals |
Who spoke
BEAT Bladder Cancer Australia · Medical Oncology Group · New York Heart Association
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.